Ventricular-assist device therapy in children

Koichi Yuki1, Ruchika Sharma, James DiNardo

  • 1Division of Cardiac Anesthesia, Department of Anesthesiology, Perioperative and Pain Medicine, Children's Hospital Boston, Boston, MA 02115, USA. koichi.yuki@childrens.harvard.edu

Insights

Mechanical circulatory support devices, such as ventricular assist devices (VADs), are crucial for children with heart failure. This review covers VADs for pediatric patients and anesthesia management for VAD implantation and non-cardiac surgeries.

Area of Science:

  • Pediatric cardiology
  • Cardiovascular surgery
  • Anesthesiology

Background:

  • Mechanical circulatory support (MCS) is vital for managing pediatric circulatory failure.
  • Ventricular assist device (VAD) technology is rapidly advancing for pediatric applications.
  • Anesthetic management for VAD implantation and care in non-cardiac surgery is complex.

Purpose of the Study:

  • To review current and emerging VADs for pediatric patients.
  • To discuss anesthetic considerations for VAD implantation in children.
  • To outline anesthetic strategies for children with VADs undergoing non-cardiac surgery.

Main Methods:

  • Literature review of VADs in pediatric populations.
  • Analysis of anesthetic management protocols for VAD implantation.
  • Review of anesthetic guidelines for patients with VADs undergoing non-cardiac procedures.

Main Results:

  • Overview of available and investigational VADs suitable for pediatric use.
  • Key anesthetic techniques and monitoring strategies for VAD implantation.
  • Perioperative anesthetic management of VAD patients for non-cardiac surgery.

Conclusions:

  • VADs represent a critical therapeutic option for pediatric heart failure.
  • Specialized anesthetic care is essential for successful VAD implantation and management.
  • Optimized anesthetic protocols improve outcomes for VAD patients undergoing non-cardiac surgery.

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiopulmonary Resuscitation III: AED Use01:23

Cardiopulmonary Resuscitation III: AED Use

Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...